Table 1.
Associations of confounders with CMV IMD alleles.
| CMV+ patient group | CMV– patient group | |||||
|---|---|---|---|---|---|---|
|
IMD Allele+ n = 75 |
IMD Allele– n = 52 |
P-value | IMD Allele+ n = 63 |
IMD Allele– n = 26 |
P-value | |
| Patient median age (years) | 59 range 20–77 | 54 range 19–78 | 0.065 | 52 range 19–74 | 48 range 21–74 | 0.771 |
| Race | <0.001 | <0.001 | ||||
| Caucasian | 54 (72%) | 19 (36.5%) | 59 (94%) | 18 (69%) | ||
| AA | 16 (21%) | 19 (36.5%) | 4 (6.0%) | 6 (23%) | ||
| Other minority | 5 (7%) | 14 (27%) | 0 (0) | 2 (8%) | ||
| Paternal recipient | 25/75 (33%) | 19/52 (37%) | 0.710 | 20/63 (32%) | 6/26 (23%) | 0.455 |
| Conditioning | 0.370 | 0.053 | ||||
| MA | 40 (53%) | 32 (62%) | 44 (70%) | 12 (46%) | ||
| RIC/NMA | 35 (47%) | 20 (38%) | 19 (30%) | 14 (54%) | ||
| Disease type | 1.00 | 0.264 | ||||
| Myeloid | 44 (58.5%) | 30 (58%) | 38 (60%) | 12 (46%) | ||
| Lymphoid | 29 (38.5%) | 21 (40%) | 23 (37%) | 14 (54%) | ||
| Aplastic Anemia | 2 (3%) | 1 (2%) | 2 (3%) | 0 (0) | ||
| RDRI | 0.115 | 0.789 | ||||
| Low | 2 (3%) | 3 (6%) | 3 (5%) | 2 (8%) | ||
| Intermediate | 38 (52%) | 16 (31%) | 28 (46%) | 11 (42%) | ||
| High | 30 (41%) | 29 (57%) | 29 (47%) | 12 (46%) | ||
| Very High | 3 (4%) | 3 (6%) | 1 (2%) | 1 (4%) | ||
| CMV reactivation first 100 days | 60/75 (80%) | 41/52 (80%) | 0.874 | 0 | 0 | N/A |
| Median HCT-CI | 3 range 0–7 | 3 range 0–5 | 0.263 | 2 range 0–6 | 3 range 0–6 | 0.341 |
| Steroid use first 100 days | 0.852 | 1.00 | ||||
| Yes | 28 (37%) | 18 (35%) | 26 (41%) | 11 (42%) | ||
| No | 47 (63%) | 34 (65%) | 37 (59%) | 15 (58%) | ||
| Any KIR mismatch | 25/75 (33%) | 18/52 (35%) | 0.52 | 28/63 (44%) | 10/26 (38%) | 0.645 |
| Donor B haplotype | 50/73 (68%) | 30/49 (61%) | 0.566 | 43/63 (68%) | 19/26 (73%) | 0.801 |
| Neutral | 31 | 15 | 24 | 8 | ||
| Better | 10 | 10 | 15 | 7 | ||
| Best | 9 | 5 | 4 | 4 | ||
| Donor median age | 39 range 19–66 | 39 range 18–67 | 0.578 | 44 range 18–68 | 49 range 24–63 | 0.332 |
| Donor CMV status | 0.470 | 0.071 | ||||
| Positive | 41 (55%) | 32 (62%) | 14 (22%) | 11 (42%) | ||
| Negative | 34 (45%) | 20 (38%) | 49 (78%) | 15 (58%) | ||
AA, African American; KIR, killer cell immunoglobulin-like receptor; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; MA, myeloablative; NMA, non-myeloablative; RDRI, revised disease risk index; RIC, reduced intensity conditioning.